Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell sold 105,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $160.71, for a total transaction of $16,874,550.00. Following the transaction, the chief executive officer now directly owns 1,027,186 shares in the company, valued at approximately $165,079,062. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.11% during mid-day trading on Wednesday, hitting $164.01. 783,042 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 1-year low of $100.89 and a 1-year high of $185.43. The stock has a 50-day moving average of $161.6 and a 200-day moving average of $161.8. The company has a market cap of $32.444 billion and a P/E ratio of 80.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 24th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $5.01 EPS for the current fiscal year.

ALXN has been the subject of a number of recent research reports. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $183.00.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.